What was reported
SOUTH SAN FRANCISCO, Calif. – August 4, 2026 – Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
What the evidence supports
Twist Bioscience told the SEC (Form 8-K, Item 1.01) that it entered into a financing arrangement or sold its securities. The filing gives Aug 4, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
How much money will actually be raised or drawn, at what final price, and how it will be used beyond what the company stated. Stated amounts can be maximums or targets rather than money already received.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $250.0 million | “SOUTH SAN FRANCISCO, Calif. – August 4, 2026 – Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock.” Mentions: offering |
| $37.5 million | “In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock.” Mentions: grant |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineTwist Bioscience Announces Proposed Public Offering of $250.0 Million of Common StockU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Press release lead paragraphSOUTH SAN FRANCISCO, Calif. – August 4, 2026 – Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Amount stated in press releaseSOUTH SAN FRANCISCO, Calif. – August 4, 2026 – Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Amount stated in press releaseIn addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.